Target intelligence / Profile preview

Methylaspartate ammonia-lyase (MAL)

Target
MAL
Molecular classification
Enzyme, Lyase (specifically, ammonia lyase), Member of the enolase superfamily
01

Overview

Methylaspartate ammonia-lyase is an enzyme (EC 4.3.1.2) predominantly found in certain bacteria (e.g., Citrobacter, Clostridium), where it plays a key role in the catabolism of glutamate via the methylaspartate pathway and in nitrogen metabolism. The enzyme catalyzes the reversible deamination of L-threo-3-methylaspartate to produce mesaconate and ammonia, employing magnesium or cobamide as cofactors. Structurally, it is a homodimer with a TIM barrel domain and belongs to the enolase superfamily. MAL’s catalytic mechanism involves abstraction of a proton alpha to the carboxyl group of methylaspartate, followed by elimination of ammonia, a process important for bacterial fermentation in anaerobic conditions. There are no clinically relevant drugs, safety concerns, or disease roles associated with this enzyme in humans, but it is a well-characterized tool in microbial biochemistry and metabolic engineering[1][2][3][4][5][7][10].

Other names
Beta-methylaspartase3-methylaspartaseL-threo-3-methylaspartate ammonia-lyase
02

Mechanism of action

Catalyzes the reversible alpha,beta-elimination of ammonia from L-threo-3-methylaspartic acid to form mesaconate Requires magnesium (Mg2+) or, in some forms, cobamide as cofactors[1][2][3] Utilizes a base-catalyzed abstraction of a proton followed by elimination of ammonia, forming an enolate intermediate[5][7]

03

Biological functions

Amino acid metabolism (specifically, deamination)Participation in c5-branched dibasic acid metabolismParticipation in nitrogen metabolismSecond step of fermentation of glutamate
04

Disease associations

Other (no major established link to human disease; primarily a bacterial enzyme involved in metabolism[4][5])
05

Safety considerations

None relevant to therapy, as this is a bacterial enzyme not targeted by human drugs and there are no reports of notable toxicities or safety issues[3][6]
06

Interacting drugs

None reported (no clinically used drugs known to target this enzyme[3][6]; a few inhibitors and substrate analogs are described in biochemical studies[9])
07

Biomarkers

3-Methylaspartase (methylaspartate ammonia-lyase) activity can serve as a marker enzyme for the mesaconate pathway in certain bacteria, but there are no clinical biomarkers for patient selection or efficacy monitoring in humans[4]

Beyond the preview

Go deeper on Methylaspartate ammonia-lyase (MAL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methylaspartate ammonia-lyase (MAL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call